86 related articles for article (PubMed ID: 12805235)
1. Apolipoprotein A-II: active or passive role in familial combined hyperlipidemia.
Aouizerat BE; Kane JP
Circ Res; 2003 Jun; 92(11):1179-81. PubMed ID: 12805235
[No Abstract] [Full Text] [Related]
2. Expression of human apoAII in transgenic rabbits leads to dyslipidemia: a new model for combined hyperlipidemia.
Koike T; Kitajima S; Yu Y; Li Y; Nishijima K; Liu E; Sun H; Waqar AB; Shibata N; Inoue T; Wang Y; Zhang B; Kobayashi J; Morimoto M; Saku K; Watanabe T; Fan J
Arterioscler Thromb Vasc Biol; 2009 Dec; 29(12):2047-53. PubMed ID: 19778946
[TBL] [Abstract][Full Text] [Related]
3. Biochemical and genetic association of plasma apolipoprotein A-II levels with familial combined hyperlipidemia.
Allayee H; Castellani LW; Cantor RM; de Bruin TW; Lusis AJ
Circ Res; 2003 Jun; 92(11):1262-7. PubMed ID: 12738753
[TBL] [Abstract][Full Text] [Related]
4. Familial combined hyperlipidemia. Part I. Lipid values and the lipoprotein pattern.
Vaverková H; Weinbergová O; Horcicka V; Kubasta M; Vrublovský P
Acta Univ Palacki Olomuc Fac Med; 1986; 113():193-216. PubMed ID: 2941985
[No Abstract] [Full Text] [Related]
5. Paradoxical exacerbation of combined hyperlipidemia in human apolipoprotein A-II transgenic mice treated with fenofibrate.
Ribas V; Palomer X; Roglans N; Rotllan N; Fievet C; Tailleux A; Julve J; Laguna JC; Blanco-Vaca F; Escolà-Gil JC
Biochim Biophys Acta; 2005 Dec; 1737(2-3):130-7. PubMed ID: 16226489
[TBL] [Abstract][Full Text] [Related]
6. Effect of combination nicotinic acid and gemfibrozil treatment on intermediate density lipoprotein, and subclasses of low density lipoprotein and high density lipoprotein in patients with combined hyperlipidemia.
Superko HR; Garrett BC; King SB; Momary KM; Chronos NA; Wood PD
Am J Cardiol; 2009 Feb; 103(3):387-92. PubMed ID: 19166694
[TBL] [Abstract][Full Text] [Related]
7. Apolipoprotein A-II, genetic variation on chromosome 1q21-q24, and disease susceptibility.
Martín-Campos JM; Escolà-Gil JC; Ribas V; Blanco-Vaca F
Curr Opin Lipidol; 2004 Jun; 15(3):247-53. PubMed ID: 15166779
[TBL] [Abstract][Full Text] [Related]
8. Human apolipoprotein A-II enrichment displaces paraoxonase from HDL and impairs its antioxidant properties: a new mechanism linking HDL protein composition and antiatherogenic potential.
Ribas V; Sánchez-Quesada JL; Antón R; Camacho M; Julve J; Escolà-Gil JC; Vila L; Ordóñez-Llanos J; Blanco-Vaca F
Circ Res; 2004 Oct; 95(8):789-97. PubMed ID: 15388641
[TBL] [Abstract][Full Text] [Related]
9. Haplotype analyses of the APOA5 gene in patients with familial combined hyperlipidemia.
van der Vleuten GM; Isaacs A; Zeng WW; ter Avest E; Talmud PJ; Dallinga-Thie GM; van Duijn CM; Stalenhoef AF; de Graaf J
Biochim Biophys Acta; 2007 Jan; 1772(1):81-8. PubMed ID: 17157483
[TBL] [Abstract][Full Text] [Related]
10. Can we exclude the TXNIP gene as a candidate gene for familial combined hyperlipidemia?
van der Vleuten GM; Hijmans A; Heil S; Blom HJ; Stalenhoef AF; de Graaf J
Am J Med Genet A; 2006 May; 140(9):1010-2. PubMed ID: 16575890
[No Abstract] [Full Text] [Related]
11. [Familial combined hyperlipidemia. I. Variation in the lipoprotein picture].
Vaverková H; Weinbergová O; Horcicka V; Kubasta M; Vrublovský P
Vnitr Lek; 1986 Sep; 32(9):878-86. PubMed ID: 3765425
[No Abstract] [Full Text] [Related]
12. Newly identified apolipoprotein AV gene predisposes to high plasma triglycerides in familial combined hyperlipidemia.
Ribalta J; Figuera L; Fernández-Ballart J; Vilella E; Castro Cabezas M; Masana L; Joven J
Clin Chem; 2002 Sep; 48(9):1597-600. PubMed ID: 12194944
[No Abstract] [Full Text] [Related]
13. Serum leptin concentrations in patients with combined hyperlipidemia: relationship to serum lipids and lipoproteins.
Haluzík M; Fiedler J; Nedvídková J; Ceska R
Physiol Res; 1999; 48(5):363-8. PubMed ID: 10625225
[TBL] [Abstract][Full Text] [Related]
14. [Familial combined hyperlipidemia: detection and characterisation of the hyperlipidemic profile among children and adolescents].
Ribalta J; La Ville AE; Heras M; Plana N; Masana L
Med Clin (Barc); 1997 Jun; 109(5):161-4. PubMed ID: 9289537
[TBL] [Abstract][Full Text] [Related]
15. Association of the APOLIPOPROTEIN A1/C3/A4/A5 gene cluster with triglyceride levels and LDL particle size in familial combined hyperlipidemia.
Mar R; Pajukanta P; Allayee H; Groenendijk M; Dallinga-Thie G; Krauss RM; Sinsheimer JS; Cantor RM; de Bruin TW; Lusis AJ
Circ Res; 2004 Apr; 94(7):993-9. PubMed ID: 15001527
[TBL] [Abstract][Full Text] [Related]
16. [Fifty years studying hiperlipidemias: the case of familial combined hyperlipidemia].
Aguilar-Salinas C; Gómez-Díaz R; Tusié-Luna MT
Invest Clin; 2010 Jun; 51(2):145-58. PubMed ID: 20928976
[TBL] [Abstract][Full Text] [Related]
17. Factors associated with postprandial lipemia and apolipoprotein A-V levels in individuals with familial combined hyperlipidemia.
Almeda-Valdes P; Cuevas-Ramos D; Mehta R; Muñoz-Hernandez L; Cruz-Bautista I; Perez-Mendez O; Tusie-Luna MT; Gomez-Perez FJ; Pajukanta P; Matikainen N; Taskinen MR; Aguilar-Salinas CA
BMC Endocr Disord; 2014 Nov; 14():90. PubMed ID: 25425215
[TBL] [Abstract][Full Text] [Related]
18. A study of familial combined hyperlipidemia in 11 families.
Das SK; Chandra M; Shukla RN; Nityanand S; Agarwal SS
Indian J Med Res; 1983 Nov; 78():665-9. PubMed ID: 6671713
[No Abstract] [Full Text] [Related]
19. Prothrombotic markers in familial combined hyperlipidemia: evidence of endothelial cell activation and relation to metabolic syndrome.
Georgieva AM; Cate HT; Keulen ET; van Oerle R; Govers-Riemslag JW; Hamulyák K; van der Kallen CJ; Van Greevenbroek MM; De Bruin TW
Atherosclerosis; 2004 Aug; 175(2):345-51. PubMed ID: 15262191
[TBL] [Abstract][Full Text] [Related]
20. [Combined familial hyperlipidemia. Study of a family].
Ahumada-Ayala M; Lozano-Castañeda O; Rull JA; Valles VE; Wong B
Rev Invest Clin; 1984; 36(2):141-5. PubMed ID: 6484332
[No Abstract] [Full Text] [Related]
[Next] [New Search]
